Key result
Circulating sACE2 levels did not significantly differ between severe and non-severe COVID-19 patients (SMD 0.3; 95% CI -0.06-0.7; P=0.1), suggesting it is not a useful prognostic biomarker.
Why the study?
Tools are urgently needed to help clinicians evaluate and manage high-risk COVID-19 patients, motivating investigation into whether sACE2 can serve as a prognostic biomarker.
Do circulating levels of sACE2 predict disease severity in COVID-19 patients?
Population
COVID-19 patients and healthy controls across 6 included studies
Comparison
COVID-19 patients (severe vs non-severe) vs healthy controls
Design
Meta-analysis
Authors
Loading...
sACE2 levels show no association with COVID-19 severity; leaves open its prognostic value in other contexts or with serial measurement.
Meta-Analysis
Do circulating levels of sACE2 predict disease severity in COVID-19 patients?
Standardized Mean Difference: 0.3 (95% CI -0.06–0.7)
p-value: p=0.1
Circulating levels of ACE2 cannot be used as a reliable biomarker to assess disease severity in COVID-19 patients.
Rahimzadeh et al. (2022) conducted a meta-analysis in COVID-19. sACE2 (soluble angiotensin-converting enzyme 2) levels vs. Non-severe COVID-19 patients and healthy controls was evaluated on ACE-2 serum or plasma levels (severe vs non-severe COVID-19) (SMD 0.3, 95% CI -0.06-0.7, p=0.1). Circulating sACE2 levels did not significantly differ between severe and non-severe COVID-19 patients (SMD 0.3; 95% CI -0.06-0.7; P=0.1), suggesting it is not a useful prognostic biomarker.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: